slx-4090
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02434744)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
Microsomal triglyceride transfer protein inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cccc(C(=O)Nc2ccc3c(c2)CCN(C(=O)Oc2ccccc2)C3)c1-c1ccc(C(F)(F)F)cc1- Mol. weight
- 546.55 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297326 ↗
Also known as
- kd026
- slx-4090
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02434744 | Phase 2 | Apr 1, 2015 | Kadmon |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kadmon | For profit | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1